My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes - Episode 5

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

, ,

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Current Time 0:00
Duration 6:03
Loaded: 0%
Stream Type LIVE
Remaining Time 6:03
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Patient with Newly Diagnosed CLL with High-Risk Features
EP. 2: Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL
EP. 3: Navigating Continuous BTKi Therapy for CLL in the 1L Setting
EP. 4: Implications of Real-World Data in the 1L Treatment of High-Risk CLL
Now Viewing
EP. 5: Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL
EP. 6: Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL
EP. 7: Perspectives on Shared Decision-Making in the Treatment of CLL
EP. 8: Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL
EP. 9: Expert Insights for Long-Term Treatment Planning in CLL
EP. 10: Patient with R/R CLL Treated with 2L Venetoclax Therapy
EP. 11: Navigating 2L Treatment Options in CLL
EP. 12: Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications
EP. 13: Management Strategies for BTKi-Related CVAEs in CLL
EP. 14: Updates in CLL Treatment Strategies with Noncovalent BTKis
EP. 15: Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following questions:

  • Discuss the role of venetoclax-based first-line (1L) combination treatment strategies.
    • How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
x